4.7 Article

11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis

期刊

JOURNAL OF AUTOIMMUNITY
卷 92, 期 -, 页码 104-113

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jaut.2018.05.010

关键词

-

资金

  1. Arthritis Research UK Centre of Excellence
  2. Arthritis Research UK grants [19859, 20843]
  3. Arthritis Research UK Centre of Excellence for the Pathogenesis of Rheumatoid Arthritis
  4. MRC Arthritis Research UK Centre for Musculoskeletal Ageing Research
  5. BBSRC [BB/G023468/1] Funding Source: UKRI

向作者/读者索取更多资源

Objective: In rheumatoid arthritis, the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is highly expressed at sites of inflammation, where it converts inactive glucocorticoids (GC) to their active counterparts. In conditions of GC excess it has been shown to be a critical regulator of muscle wasting and bone loss. Here we examine the contribution of 11 beta-HSD1 to the pathology of persistent chronic inflammatory disease. Methods: To determine the contribution of 11 beta-HSD1 to joint inflammation, destruction and systemic bone loss associated with persistent inflammatory arthritis, we generated mice with global and mesenchymal specific 11 beta-HSD1 deletions in the TNF-transgenic (TNF-tg) model of chronic polyarthritis. Disease severity was determined by clinical scoring. Histology was assessed in formalin fixed sections and fluorescence-activated cell sorting (FACS) analysis of synovial tissue was performed. Local and systemic bone loss were measured by micro computed tomography (micro-CT). Measures of inflammation and bone metabolism were assessed in serum and in tibia mRNA. Results: Global deletion of 11 beta-HSD1 drove an enhanced inflammatory phenotype, characterised by florid synovitis, joint destruction and systemic bone loss. This was associated with increased pannus invasion into subchondral bone, a marked polarisation towards pro-inflammatory M1 macrophages at sites of inflammation and increased osteoclast numbers. Targeted mesenchymal deletion of 11 beta-HSD1 failed to recapitulate this phenotype suggesting that 11 beta-HSD1 within leukocytes mediate its protective actions in vivo. Conclusions: We demonstrate a fundamental role for 11 beta-HSD1 in the suppression of synovitis, joint destruction, and systemic bone loss. Whilst a role for 11 beta-HSD1 inhibitors has been proposed for metabolic complications in inflammatory diseases, our study suggests that this approach would greatly exacerbate disease severity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据